Drug-induced Lung Disease in the Oncology Patient: From Cytotoxic Agents to Immunotherapy.

Autor:	Shroff GS; Department of Thoracic Imaging, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1478, Houston, TX 77030, USA. Electronic address: gshroff@mdanderson.org., Sheshadri A; Department of Pulmonary Medicine, University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Unit 1462, Houston, TX 77030, USA., Altan M; Department of Thoracic Head & Neck Medical Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 0432, Houston, TX 77030, USA., Truong MT; Department of Thoracic Imaging, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1478, Houston, TX 77030, USA., Erasmus LT; McGill University, 845 Sherbrooke Street West, Montreal, Quebec H3A 0G4, Canada., Vlahos I; Department of Thoracic Radiology, University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Unit 1478, Houston, TX 77030, USA.
Jazyk:	angličtina
Zdroj:	Clinics in chest medicine [Clin Chest Med] 2024 Jun; Vol. 45 (2), pp. 325-337. Date of Electronic Publication: 2024 Mar 23.
DOI:	10.1016/j.ccm.2024.02.006
Abstrakt:	Drug-induced lung disease is commonly encountered, especially in the oncology setting. Diagnosis is challenging because clinical and radiologic findings are nonspecific, often overlapping with other lung pathologies in these patients due to underlying neoplasia, infection, or other treatment effects such as radiotherapy. Furthermore, oncology patients often receive multiple antineoplastic agents concurrently, and virtually every agent has an association with lung injury. In this article, we will review a variety of antineoplastic agents that are associated with drug-induced injury and discuss incidence, their typical timing of onset, and imaging features. Competing Interests: Disclosure The authors have nothing to disclose. (Copyright © 2024 Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu